Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

3SBio (1530 HK) Placement: 3SBio’s Pipeline Strength, An Indirect Stake in Mandi Makes It Attractive

Equity Capital Markets

<ul>
<li>Mandi has filed for a Hongkong IPO. The company which at present operates as a subsidiary of 3SBio Inc will be spun off and separately listed.</li>
<li>Mandi intends to use the IPO proceeds for funding product expansion, enhance early-stage R&amp;D capabilities, invest in sales and marketing initiatives and, for working capital and general corporate purposes.</li>
<li>Minoxidil will be the main growth catalyst for now cashing on its leadership position while accelerating the development and commercialization of the pipeline assets will be key for future growth.</li>
</ul>


Mandi has filed for a Hongkong IPO. The company which at present operates as a subsidiary of 3SBio Inc will be spun off and separately listed.
Mandi intends to use the IPO proceeds for funding product expansion, enhance early-stage R&amp;D capabilities, invest in sales and marketing initiatives and, for working capital and general corporate purposes.
Minoxidil will be the main growth catalyst for now cashing on its leadership position while accelerating the development and commercialization of the pipeline assets will be key for future growth.


Mandi Inc Pre IPO: Hair Will Help Carry Weight to Future Growth, Pipeline Key